Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Canagliflozin

FDA-approved product (tablet, oral), marketed as Canagliflozin, Invokana.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Canagliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Canagliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Canagliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

    NCT02025907 · start 2014-02

    Registered record
    Registry ID
    NCT02025907
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Canagliflozin, 100 mg; Canagliflozin, 300 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-02
    Completion
    2015-09
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionCanagliflozin, 100 mg; Canagliflozin, 300 mg; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

    NCT02073227 · start 2014-02

    Registered record
    Registry ID
    NCT02073227
    Conditions
    Healthy Volunteers
    Interventions
    Canagliflozin, 300 mg; Metformin XR, 500 mg; CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg; CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-06
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCanagliflozin, 300 mg; Metformin XR, 500 mg; CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg; CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

    NCT01989754 · start 2014-01-16

    Registered record
    Registry ID
    NCT01989754
    Conditions
    Diabetes Mellitus, Type 2; Albuminuria
    Interventions
    Placebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01-16
    Completion
    2017-02-23
    Enrolment
    5,813

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Albuminuria
    InterventionPlacebo; Canagliflozin, 100 mg; Canagliflozin, 300 mg
    PhasePhase 4
    Registry statusCompleted

  • A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus

    NCT01483781 · start 2011-12

    Registered record
    Registry ID
    NCT01483781
    Conditions
    Diabetes Mellitus, Type 2; Plasma Volume
    Interventions
    Canagliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-12
    Completion
    2012-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Plasma Volume
    InterventionCanagliflozin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

    NCT01381900 · start 2011-08

    Registered record
    Registry ID
    NCT01381900
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Placebo; Canagliflozin 100mg; Canagliflozin 300mg; Metformin; Sulphonylurea
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-11
    Enrolment
    678

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPlacebo; Canagliflozin 100mg; Canagliflozin 300mg; Metformin +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

    NCT01381887 · start 2011-06

    Registered record
    Registry ID
    NCT01381887
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Placebo; Canagliflozin 300mg/Placebo; Canagliflozin 300mg/Canagliflozin 150mg; Canagliflozin 300mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-11
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPlacebo; Canagliflozin 300mg/Placebo; Canagliflozin 300mg/Canagliflozin 150mg; Canagliflozin 300mg
    PhasePhase 1
    Registry statusCompleted

  • Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

    NCT01387737 · start 2011-05

    Registered record
    Registry ID
    NCT01387737
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    TA-7284-Low; TA-7284-High
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-12
    Enrolment
    1,299

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionTA-7284-Low; TA-7284-High
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

    NCT01294631 · start 2011-03

    Registered record
    Registry ID
    NCT01294631
    Conditions
    Healthy
    Interventions
    Canagliflozin 300 mg once daily and HCTZ 25 mg once daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin 300 mg once daily and HCTZ 25 mg once daily
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers

    NCT01718652 · start 2011-02

    Registered record
    Registry ID
    NCT01718652
    Conditions
    Healthy
    Interventions
    Canagliflozin (JNJ-28431754); Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2011-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin (JNJ-28431754); Cyclosporine
    PhasePhase 1
    Registry statusCompleted

  • A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

    NCT01173549 · start 2010-11

    Registered record
    Registry ID
    NCT01173549
    Conditions
    Healthy
    Interventions
    Canagliflozin/Placebo Placebo/Canagliflozin; no intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-11
    Completion
    2011-09
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin/Placebo Placebo/Canagliflozin; no intervention
    PhasePhase 1
    Registry statusCompleted

  • The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

    NCT01106690 · start 2010-06

    Registered record
    Registry ID
    NCT01106690
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Placebo; Canagliflozin; Sitagliptin; Metformin; Pioglitazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2012-07
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPlacebo; Canagliflozin; Sitagliptin; Metformin +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

    NCT01157000 · start 2010-05

    Registered record
    Registry ID
    NCT01157000
    Conditions
    Healthy
    Interventions
    Canagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05
    Completion
    2010-06
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin
    PhasePhase 1
    Registry statusCompleted

  • The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

    NCT01081834 · start 2010-03

    Registered record
    Registry ID
    NCT01081834
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Canagliflozin; Placebo; Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-03
    Enrolment
    678

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionCanagliflozin; Placebo; Sitagliptin
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.

    NCT01714206 · start 2009-06

    Registered record
    Registry ID
    NCT01714206
    Conditions
    Healthy
    Interventions
    Digoxin 0.5 mg; Digoxin 0.25 mg; Canagliflozin (JNJ-28431754)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2009-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDigoxin 0.5 mg; Digoxin 0.25 mg; Canagliflozin (JNJ-28431754)
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers

    NCT01821027 · start 2008-08

    Registered record
    Registry ID
    NCT01821027
    Conditions
    Healthy
    Interventions
    Simvastatin; Canagliflozin (JNJ-28431754)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2008-09
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSimvastatin; Canagliflozin (JNJ-28431754)
    PhasePhase 1
    Registry statusCompleted